Biopharma and med-tech companies raising money in public or private financings, including: Antiverse, Beken, Informuta, Maia, Modular, Poplar, Prolium, Xsensio.
Polares Medical SA raised $50 million in a series C financing round for Mrace, its posterior leaflet replacement system designed to treat mitral regurgitation.
Antiverse Ltd. has announced the close of a $9.3 million series A financing. The funding will support expansion of the company’s proprietary AI antibody design platform, accelerate development of its internal therapeutic pipeline, and advance lead antibody programs toward in vivo efficacy studies.
Biopharma and med-tech companies raising money in public or private financings, including: Beone, Defence, Edison, Jazz, Royalty, Sharp, Telo Genomics, Zymeworks.
Generate Biomedicines Inc. proved that enthusiasm hasn’t waned for TSLP as a target by pricing an IPO selling 25 million shares at $16 each for proceeds of $400 million. Generate’s lead compound is phase III-stage TSLP-targeting antibody GB-0895 and the company’s assigned Nasdaq ticker is GENB. The offering is expected to close on March 2.
Biopharma and med-tech companies raising money in public or private financings, including: Abram, Bicara, Breezebio, Octapharma, Respiree, Trinity, Zura.
At Biocom’s Global Partnering and Investor Conference, venture capitalists (VCs) on multiple panels offered their thoughts on the state of venture investing and offered advice for startups interested in securing funding. Sentiment for early stage investment was somewhat mixed, but trended negative as VCs acknowledged that it’s a tough environment in which to raise capital.
RSS
